• Vaccine Name: E. tenella vaccine rBCG pMV261-Rho
• Target Pathogen: Eimeria tenella
• Target Disease: Hemorrhagic cecal coccidiosis
• Vaccine Ontology ID: VO_0011472
• Type: Recombinant vector vaccine
• Status: Research
• Antigen: Eimeria tenella rhomboid gene (Rho)
• Rho gene engineering:
  • Type: Recombinant vector construction
  • Description: The rhomboid gene segment (GenBank accession no. DQ323509) was generated from the cDNA of E. tenella strains by PCR with primers QF (5’-CTGACTGCAGATGTCGGACATCGAATCCCAGAG-3′) containing PstI restriction site (underlined) and QR (5’-GACTATCGATTTATGCGCATCCCATGGGCAAAGG-3’) containing ClaI restriction site (underlined), and cloned into the pMD18-T vector. The 774-bp rhomboid gene fragment was subcloned into the PstI/ClaI sites of pMV261. The plasmid pMV261-Rho was electrotransfected into BCG and selected by kanamycin (Sigma) (Wang et al., 2009).
  • Detailed Gene Information: Click Here.
• Immunization Route: Intravenous injection (i.v.)

Chicken Response

• Vaccination Protocol: Chickens were randomly assigned to 4 groups (40 birds in each group) and immunized intranasal (i.n.) with 10^6 CFU/200 μl of BCG or rBCG strains expressing rhomboid protein, respectivelly. Negative control was immunized i.n. with 200 μl PBS only. 2 weeks after the first vaccination, a second immunization was carried out with the same amounts of each sample (Wang et al., 2009).
• Challenge Protocol: All groups were challenged with 3 × 10^4 sporulated oocysts of E. tenella per bird 2 weeks after the final immunization (Wang et al., 2009).
• Efficacy: All the recombinant BCG immunized chickens developed specific immune responses, and there was a significant increases of the percentages of CD4(+) and CD8(+) cells compared to the control (P<0.05). Challenge experiments demonstrated that the two rBCG strains could provide significant protection against E. tenella challenge (Wang et al., 2009).